This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.

Explore ELIQUIS®

Materials for patients who have been prescribed ELIQUIS

Patient Information
Booklet – For stroke
prevention in NVAF

Patient Information Booklet – For
stroke prevention in NVAF – Switching
from warfarin

Patient Information
Booklet – DVT / PE

Patient Information Booklet – VTE
prophylaxis in patients who
have undergone hip / knee
replacement surgery


DVT = Deep Vein Thrombosis   NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   VTE = Venous Thromboembolism